Home › Gilead Sciences tops 3Q earnings and revenue expectations
 

Keywords :   


Gilead Sciences tops 3Q earnings and revenue expectations

2015-10-28 12:51:57| Biotech - Topix.net

Propelled by skyrocketing sales of its breakthrough hepatitis C pills, Gilead Sciences Inc. posted an impressive 68 per cent increase in third-quarter profit and hiked its revenue forecast yet again. The Forest City, California, company has what amounts to a license to print money in its Harvoni, the first once-daily, single-pill regimen for hepatitis C, and predecessor drug Sovaldi, both launched in the last two years.

Tags: sciences revenue expectations tops

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Sheboygan Paint Company Appoints New Technical Sales Representative
20.05GK Hair Unveils Summer 2024s Must-Have Hair Trends
20.05Revlon Taps Under Armour\'s Tchernavia Rocker As New Chief People Officer
20.05Canada invests over $9.6M to prevent, prepare for African swine fever
20.05Dabbagh Named General Manager of Waldencast Ventures Glaze Brand
20.05Pretty Little Thing warned over 'misleading' ads
20.05Several pork priorities secured in House Farm Bill
20.05BT scraps digital landline switch deadline
More »